MagicMed

MagicMed’s mission is to unlock the full potential of psychedelic-derived medicines. The company is focused on the discovery and development of novel drug candidates, structurally related to classic psychedelics but with improved pharmaceutical characteristics.

Ico 1 1

Multiple Indications

Patented molecules can address multiple psychological indications

Ico 2

Various Psychedelics

MagicMed has filed patents in psilocybin/N.N-dimethyltryptamine (DMT) derivatives and will expand to other psychedelics

Ico 3

Complementary Sector Market Share

Platform play for the industry that does not cannibalize on sector market share

Ico 4

De-risked Revenue Model with Blue Sky Potential

Revenue across the drug development stages with diversified upside potential

Ico 5

Multiple Partnerships

Licensing deals can be done with multiple partners

Ico 6

Conservative Capital Market Strategies

Designed to be quickly cash flow positive and to come to market for capital only upon accretive or transformative events

Keep up to date with the latest developments

UPCOMING EVENTS

Date Event REGISTER
20-22 April 2021 2:00pm EST Planet MicroCap Showcase (This includes a panel discussion)
27 April 2021 2-4pm EST AMA Shroomstock Event
27 April 2021 SPAC Opportunity Summit
4-6 May 2021 10:30 CT Psychedelic Therapeutics and Drug Development Conference
10-11, 14-18 June 2021 Bio Digital Conference
17 June 2021 Psychedelics in Psychiatry and Beyond Conference (H.C. Wainwright)
22-23 June 2021 Psychedelic Opportunity Summit (This includes a presentation and panel discussion)

LATEST PRESS RELEASES